Daiichi Sankyo Presents Results of Quizartinib in P-III (QuANTUM-First) Study for the Treatment of FLT3-ITD Positive Acute Myeloid Leukemia at EHA2022
- The P-III (QuANTUM-First) study evaluated quizartinib + CT vs CT alone in a ratio (1:1) in 539 patients aged 18-75yrs. with FLT3-ITD+ AML at 193 sites across Asia, EU, North & South America & Oceania
- The results showed OS benefits with m-OS (31.9mos. vs 15.1mos.) after a median follow-up of 39.2mos., 22.4% reduction in risk of death & the safety profile was manageable with no new safety signals, rates of TEAEs associated with fatal outcomes (11.3% vs 9.7%)
- 0.8% discontinued treatment due to QT prolongation, 0.8% experienced cardiac arrest with V-fib on ECG, CRc rate (71.6% vs 64.9%), rates of CR (54.9% vs 55.4%), the median duration of CR (38.6mos. vs 12.4mos.), m-RFS (39.3mos vs 13.6mos.) with 38.7% relative risk reduction of relapse or death
Ref: Businesswire | Image: Daiichi Sankyo
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.